Analyzing Celyad Oncology (NASDAQ:CYAD) & Alterity Therapeutics (NASDAQ:ATHE)

Celyad Oncology (NASDAQ:CYADGet Rating) and Alterity Therapeutics (NASDAQ:ATHEGet Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.

Profitability

This table compares Celyad Oncology and Alterity Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celyad Oncology N/A N/A N/A
Alterity Therapeutics N/A N/A N/A

Analyst Recommendations

This is a summary of current ratings for Celyad Oncology and Alterity Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celyad Oncology 1 1 1 0 2.00
Alterity Therapeutics 0 1 1 0 2.50

Celyad Oncology presently has a consensus target price of $6.89, indicating a potential upside of 273.14%. Alterity Therapeutics has a consensus target price of $2.50, indicating a potential upside of 331.18%. Given Alterity Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Alterity Therapeutics is more favorable than Celyad Oncology.

Earnings & Valuation

This table compares Celyad Oncology and Alterity Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celyad Oncology $10,000.00 4,171.98 -$31.37 million N/A N/A
Alterity Therapeutics $3.37 million 3.89 -$9.32 million N/A N/A

Alterity Therapeutics has higher revenue and earnings than Celyad Oncology.

Insider and Institutional Ownership

29.1% of Celyad Oncology shares are owned by institutional investors. Comparatively, 3.2% of Alterity Therapeutics shares are owned by institutional investors. 0.9% of Celyad Oncology shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Celyad Oncology has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.

Summary

Alterity Therapeutics beats Celyad Oncology on 5 of the 8 factors compared between the two stocks.

About Celyad Oncology

(Get Rating)

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

About Alterity Therapeutics

(Get Rating)

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.